Impact of Highly Active Antiretroviral Therapy on paediatric Human Immunodeficiency Virus-associated left ventricular dysfunction within the Johannesburg teaching hospital complex

Cardiology in the Young

Volumn 22, Issue 5, 2012, Pages 564-573

  Pepeta, Lungile ^a   Cilliers, Antoinette M ^b  

^a WALTER SISULU UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

immunological status; Myocardial function; nutritional status

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; CARVEDILOL; DIDANOSINE; DIGITALIS; DIGOXIN; EFAVIRENZ; ENALAPRIL; FUROSEMIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; POTASSIUM; SPIRONOLACTONE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CARDIOMYOPATHY; CD4 LYMPHOCYTE PERCENTAGE; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOREACTIVITY; INFANT; LACTIC ACIDOSIS; MALE; MEDICAL RECORD REVIEW; MITOCHONDRIAL TOXICITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SCHOOL CHILD; SEX RATIO; TEACHING HOSPITAL; TREATMENT DURATION; VIRUS LOAD; WEIGHT GAIN;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HOSPITALS, TEACHING; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84866356252     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951112000078     Document Type: Article

References (41)

1. Lipshultz SE. Dilated cardiomyopathy in HIV infected patients. NEJM 1998; 339: 1153-1155.
2. Barbaro G, Fisher Stacy D, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Review. Lanc Infect Dis 2001; 1: 115-124.
3. Al-Attar I, Orav EJ, Exil V, Vlach SA, Lipshultz SE. Predictors of cardiac morbidity and mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 2003; 41: 1598-1605.
4. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo studio cardiologico dei pazienti affetti da AIDS. NEJM 1998; 339: 1093-1099.
5. Micon B, Jeane DP, Maarten S, Marchina VE. Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J Acquir Immune Defic Syndr 2001; 27: 318-320.
6. Starc TJ, Lipschultz SE, Kaplan S, et al. Cardiac complications in children with human immunodeficiency virus infection. Pediatrics 1999; 104: e14.
7. Barbaro G. HIV-associated cardiomyopathy etiopathogenesis and clinical aspects. Herz 2005; 30: 486-492.
8. Takawira FF. Spectrum of cardiac manifestations and complications in children with acquired immunodeficiency syndrome at Chris Hani Baragwanath Hospital. Research report submitted to the Faculty of Health Sciences of the University of the Witwatersrand in partial fulfilment of the requirements for the Master of Medicine in Paediatrics and Child Health degree, Johannesburg, 2000 (Unpublished Data).
9. Sani MU, Okeahialam BN, Aliyu SH, Enoch DA. Human immunodeficiency virus (HIV) related heart disease: a review. Wien Klin Wochenschr (Mid Euro J Med) 2005; 117/3: 73-81.
10. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40: 282-284.
11. Barbaro G. HIV infection, highly active antiretroviral therapy and the cardiovascular system. Review. Cardiovasc Res 2003; 60: 87-95.
12. Herdy GV, Pinto CA, Lopes VG, et al. Study of the cardiac alterations in HIV-infected children consequent to the antire-troviral therapy: prospective study of 47 cases. Arq Bras Cardiol 2003; 80: 311-320.
13. Diogenes MS, Carvalho AC, Succi RC. Reversible cardiomyo-pathy subsequent to perinatal infection with human immunodeficiency virus. Cardiol Young 2003; 13: 373-376.
14. Plebani A, Esposito S, Pinzani R, et al. Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection. Pediatr Infect Dis J 2004; 23: 559-563.
15. Saulsbury FT. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 464-468.
16. Damonski MJ, Sloas MM, Follmann DA, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995; 127: 137-146.
17. Department of Health of South Africa. Guidelines for the management of HIV-infected children, Jacana Media, 2005: pp 3-14.
18. 2 HIV study. J Pediatr 2002; 141: 327-335.
19. Silverman NH. Quantitative methods to enhance morphological information using M-mode, Doppler, and crossectional ultrasound. pediatric echocardiography. Williams and Wilkins, Baltimore, MD, 1993: p 38.
20. WHO Working Group. Use and Interpretation of Anthropometric Indicators of Nutritional Status. Bull World Health Organ. 1986; 64: 929-941.
21. Van Heeswijk RPG, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1 infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2002; 6: 201-229.
22. World Health Organization. Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance, African Region 2005. http://www.who.int
23. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 337-343.
24. Verweel G, van Rossum AMC, Hartwig NG, et al. Treatment with highly active antiretroviral therapy in immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002; 109: 1-7.
25. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744.
26. Behrens GMN, Stoll M, Schmidt R. Lipodystrophy syndrome in HIV infection. Drug Saf 2000; 23: 57-76.
27. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008; 61: 8-12.
28. Frericks FCP, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse transcriptase inhibitors. NEJM 2002; 347: 1895-1896.
29. Lamperth L, Dalakas MC, Dagani F, Anderson J, Ferrari R. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest 1991; 65: 742-751.
30. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlet JD. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992; 116: 311-313.
31. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991; 337: 253-260.
32. Sani MU. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr 2008; 120: 77-87.
33. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS 2003; 17: S12-S20.
34. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myo-cardial cells of HIV-positive patients. NEJM 1998; 339: 1093-1099.
35. Prendergast BD. HIV and cardiovascular medicine. Heart 2003; 89: 793-800.
36. Calabarese LH, Proffitt MR, Yen-Lieberman B, Hobbs RE, Ratliff NB. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med 1989; 107: 691-692.
37. Grody WW, Cheng L, Lewis W. Infection of the heart by the HIV. Am J Cardiol 1990; 66: 203-206.
38. Barbaro G, Di Lorenzo G, Soldini M, et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus associated cardiomyopathy. Circulation 1999; 100: 933-939.
39. Herskowitz A, Willoughby S, Wu TC, et al. Immunopathogen-esis of HIV-1 associated cardiomyopathy. Clin Immunol Immunopathol 1993; 68: 234-241.
40. Rodriguez ER, Nasim S, Hsia J, et al. Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. Am J Cardiol 1991; 68: 1511-1520.
41. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000; 43: 151-170.